Vericel (VCEL) Cash from Investing Activities (2010 - 2026)
Vericel's (VCEL) quarterly Cash from Investing Activities came in at -$4.2 million in Q1 2026, up 72.26% year-on-year from -$2.4 million in Q1 2025, and up 74.37% quarter-over-quarter from -$16.4 million in Q4 2025.
Vericel (VCEL) Cash from Investing Activities (2010 - 2026) Analysis & Trends
Vericel has disclosed Cash from Investing Activities across 17 years of filings, most recently posting -$4.2 million for Q1 2026.
- Cash from Investing Activities for Q1 2026 came in at -$4.2 million, up 72.26% year-over-year; the trailing twelve-month figure through Mar 2026 was -$33.0 million (up 51.99% YoY), and the FY2025 annual result was -$43.9 million, up 44.41% from the prior year.
- Cash from Investing Activities came in at -$4.2 million for Q1 2026 at Vericel, up from -$16.4 million in the prior quarter.
- In the past five years, Cash from Investing Activities ranged from a high of $4.6 million in Q3 2023 to a low of -$25.5 million in Q1 2024.
- The 5-year median for Cash from Investing Activities is -$9.0 million (2025), against an average of -$9.8 million.
- Across the five-year window, Cash from Investing Activities tumbled 1252.73% in 2022 and soared 663.01% in 2023, its largest moves.
- Vericel's Cash from Investing Activities stood at -$21.7 million in 2022, then jumped by 62.78% to -$8.1 million in 2023, then sank by 81.14% to -$14.7 million in 2024, then declined by 11.87% to -$16.4 million in 2025, then soared by 74.37% to -$4.2 million in 2026.
- The last three Cash from Investing Activities figures came in at -$4.2 million (Q1 2026), -$16.4 million (Q4 2025), and -$3.4 million (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Investing Activities (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | -2.89 Mn |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | 638.50 Mn |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | - |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | -431.90 Mn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | 579,519.10 |
| 10 | Vericel | 2.04 Bn | 1.90 Bn | 49.27 Mn | -4.20 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -4.20 Mn |
| Mar 31, 2026 | -4.20 Mn |
| Dec 31, 2025 | -16.39 Mn |
| Dec 31, 2025 | -16.39 Mn |
| Sep 30, 2025 | -3.38 Mn |
| Sep 30, 2025 | -3.38 Mn |
| Jun 30, 2025 | -9.03 Mn |
| Jun 30, 2025 | -9.03 Mn |
| Mar 31, 2025 | -15.14 Mn |
| Mar 31, 2025 | -15.14 Mn |
| Dec 31, 2024 | -14.65 Mn |
| Dec 31, 2024 | -14.65 Mn |
| Sep 30, 2024 | -21.21 Mn |
| Sep 30, 2024 | -21.21 Mn |
| Jun 30, 2024 | -17.72 Mn |
| Jun 30, 2024 | -17.72 Mn |
| Mar 31, 2024 | -25.45 Mn |
| Mar 31, 2024 | -25.45 Mn |
| Dec 31, 2023 | -8.09 Mn |
| Dec 31, 2023 | -8.09 Mn |